Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice $(GLP)$ toxicology studies. These efforts are aimed at supporting an Investigational New Drug $(IND.AU)$ application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。